Pharma Focus Asia

Psychogenics Has Acquired the Exclusive Global License for an IND-ready ENT1 Inhibitor Designed for the Treatment of Neuropsychiatric Disorders

Saturday, December 02, 2023

PGI Drug Discovery LLC, trading as PsychoGenics, recently secured an exclusive license agreement with Roche for the global development, manufacturing, and commercialization rights to RO7117997. This compound, identified as an Equilibrative Nucleoside Transporter 1 (ENT1) inhibitor, is IND-ready and shows promise for treating various psychiatric and neurological conditions, starting with sleep and seizure disorders.

RO7117997 originated from a collaboration between PsychoGenics and Roche, utilizing PsychoGenics' AI-enabled phenotypic screening platforms, particularly the SmartCube® platform. Dr. Emer Leahy, President and CEO of PsychoGenics, expressed satisfaction in advancing another phenotypically discovered drug candidate, emphasizing the novelty of inhibiting ENT1 for addressing neuropsychiatric disorders.

David Bleakman, PhD, President of Drug Discovery at PsychoGenics, expressed optimism about expanding their pipeline and highlighted the diverse therapeutic possibilities of ENT1 inhibitors based on pre-clinical data. RO7117997 has exhibited a compelling safety profile in non-clinical studies, and the company aims to submit an IND application and commence clinical trials in 2024.

The mechanism of action involves ENT1 inhibition, blocking the transporter's activity and preventing adenosine uptake into cells. This leads to an elevation in extracellular adenosine levels, potentially improving sleep quality and reducing seizures by activating adenosine receptors. Beyond sleep and seizure disorders, ENT1 inhibitors like RO7117997 may find applications in treating conditions such as schizophrenia, addiction, neurodegenerative disorders, pain, and inflammation. The license agreement aligns with PsychoGenics' strategic objective of developing improved treatments for severe CNS conditions.

 

Source: businesswire.com

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024